SciELO - Scientific Electronic Library Online

 
vol.41 issue2Ketamine improves survival in severe burn injury in rats via the expression of heat shock protein 70Temperature management during the perioperative period and frequency of inadvertent hypothermia in a general hospital author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Colombian Journal of Anestesiology

Print version ISSN 0120-3347

Abstract

NEUENFELDT, Tino  and  HOPF, Hans-Bernd. Sustained low efficiency dialysis as standard renal replacement therapy in an interdisciplinary intensive care unit - A five year cost-benefit analysis. Rev. colomb. anestesiol. [online]. 2013, vol.41, n.2, pp.88-96. ISSN 0120-3347.  https://doi.org/10.1016/j.rca.2013.01.002.

Background: Sustained low efficiency dialysis (SLED) as primary renal replacement therapy (RRT) in acute kidney injury (AKI) is not widely used, despite substantial economic advantages. We evaluated costs and outcome in a 5 year retrospective study on our ICU. Methods: From 2006 to 2010 we selected all patients with the ICD-10 codes N17 and N18 who were treated with SLED on our ICU. Patients with a stay <2 days, an extra-renal indication for dialysis or chronic dialysis were excluded. Variables: number of SLEDs, duration of ICU and hospital stay, ICU and hospital mortality, SAPS II, TISS 28, blood urea and creatinine, C-reactive protein, mechanical ventilation, diagnoses. Long-term outcome was evaluated by sending all discharged patients a questionnaire. Results: Between 2006 and 2010, 3247 SLED-treatments in 421 patients (mean SAPS II: 41 points without GCS) were performed. ICU and hospital mortality in the patients treated only with SLED (n = 392) was 34% and 45%, respectively. 71% of all surviving patients had good quality of life and 12% of all discharged patients still needed dialysis. Total costs for SLED were 526.819 € and total proceeds were 734.996 €. Assuming also 3247 «CWHDF-days» for cost comparisons we calculated costs of 729.991 € with proceeds of 690.864 € for CVVHDF. Conclusions: In critically ill patients with AKI SLED is an effective RRT, with short- and long-term outcome being comparable to outcome data with CVVHDF. Based on our cost-proceeds analysis SLED seems to be the preferable renal replacement therapy.

Keywords : Acute Kidney Injury; Dyalisis; Efficiency; Intensive Care; Renal Replacement Therapy.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )